A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Constellation Pharmaceuticals
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Ohio State University Comprehensive Cancer Center
University Hospital, Angers
M.D. Anderson Cancer Center
Ottawa Hospital Research Institute
Federico II University
Queen's University, Belfast
University Health Network, Toronto
Herlev Hospital
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University Hospital, Bordeaux
Incyte Corporation
Northwestern University
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
University Hospital, Geneva
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
University Hospital, Bordeaux
Novartis
Canadian Cancer Trials Group
Fred Hutchinson Cancer Center
Mayo Clinic
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Italfarmaco
Mayo Clinic
University of Utah
Icahn School of Medicine at Mount Sinai
Italfarmaco
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
University Hospital, Brest
Wake Forest University Health Sciences
Eli Lilly and Company
European Organisation for Research and Treatment of Cancer - EORTC
Icahn School of Medicine at Mount Sinai
OHSU Knight Cancer Institute
Icahn School of Medicine at Mount Sinai
California Cancer Consortium
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Traws Pharma, Inc.
Wake Forest University Health Sciences
Vanderbilt University Medical Center
Eli Lilly and Company
Fred Hutchinson Cancer Center
Galena Biopharma, Inc.
Alliance for Clinical Trials in Oncology